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Objective: This study was conducted to evaluate the effects of vitamin D supplementation on wound healing
and metabolic status in patients with diabetic foot ulcer (DFU).
Methods: This randomized, double-blind, placebo-controlled trial was performed among 60 patients with
grade 3 DFU according to "Wagner–Meggitt’s" criteria. Participants were randomly divided into two groups
(each 30 participants) and received either 50,000 IU vitamin D supplements every 2 weeks for 12 weeks
(group A) or placebo (group B). Fasting blood samples were taken at study baseline and after 12-week
intervention to determine related markers.
Results: After 12 weeks of intervention, compared with the placebo, vitamin D supplementation resulted in
a signiﬁcant reduction in ulcer length (−2.1 ± 1.1 vs.−1.1 ± 1.1 cm, P = 0.001), width (−2.0 ± 1.2 vs.
−1.1 ± 1.0 cm, P = 0.02) and depth (−1.0 ± 0.5 vs.−0.5 ± 0.5 cm, P b 0.001), and erythema rate (100% vs.
80%, P = 0.01). In addition, in supplemented patients changes in serum insulin concentration (−3.4 ± 9.2
vs. +2.8 ± 9.3 μIU/mL, P = 0.01), homeostasis model of assessment-estimated insulin resistance (−1.5 ±4.1
vs. +1.7 ± 5.1, P = 0.01), the quantitative insulin sensitivity check index (+0.006 ± 0.02 vs.−0.006 ±0.02,
P = 0.03) and HbA1c (−0.6 ± 0.6 vs. −0.1 ± 0.5%, P = 0.004) were signiﬁcantly different from those of
patients in the placebo group. Additionally, following supplementation with vitamin D, signiﬁcant reductions in
serum total- (−15.8 ± 18.9 vs. +5.3 ± 31.8 mg/dL, P = 0.003), LDL- (−17.2 ± 19.8 vs. +2.2 ± 28.6 mg/dL,
P = 0.003), total-/HDL-cholesterol ratio (−1.1 ± 0.8 vs. −0.2 ± 1.1, P = 0.001), high sensitivity C-reactive
protein (hs-CRP) (−0.4 ± 2.5 vs. +1.9 ± 4.2 μg/mL, P = 0.01), erythrocyte sedimentation rate (ESR)
(−34.7 ± 32.4 vs.−18.0 ± 26.6 mm/h, P = 0.03) and plasma malondialdehyde (MDA) concentrations
(−0.7 ± 0.9 vs. −0.2 ± 0.5 μmol/L, P = 0.008) were seen compared with the placebo.
Conclusions: Overall, vitamin D supplementation for 12 weeks among patients with DFU had beneﬁcial
effects on glucose homeostasis, total-, LDL-, total-/HDL-cholesterol, ESR, hs-CRP and MDA levels. In
addition, vitamin D may have played an indirect role in wound healing due to its effect on improved
glycemic control.© 2016 Elsevier Inc. All rights reserved.1. Introduction
The diabetic foot ulcer (DFU) is a common complication of
diabetes mellitus affecting 10%–25% of people with diabetes
(Armstrong et al., 2014). The annual incidence of ulceration and
amputation among patients with DFU is as high as 2.5%–10.7% andr: IRCT201510315623N54.
+98 31 55463377.0.25%–1.8%, respectively (Tiaka, Papanas, Manolakis, & Maltezos,
2011). Patients with diabetic foot ulcer have a higher mortality
compared with patients with diabetes who have not developed food
ulcer. DFU is a major cause of morbidity in diabetic patients, and the
mortality rate is about twice that of diabetic patients without foot
ulcer (Daousi et al., 2004). Diabetic neuropathy and peripheral
vascular disease are the main etiological factors in DFU (Sinwar,
2015). Furthermore, insulin resistance, dyslipidemia, inﬂammation
and oxidative stress play a signiﬁcant role in the pathogenesis of
DFU (Karadurmus et al., 2010; Sytze Van Dam, Cotter, Bravenboer, &
Cameron, 2013).
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roles of vitamin D inadequacy including its role in pancreatic insulin
secretion and insulin action, the immune system particularly on T cell
medicated immunity and decreased inﬂammation and oxidative
stress (Asemi, Hashemi, Karamali, Samimi, & Esmaillzadeh, 2013;
Zubair, Malik, Meerza, & Ahmad, 2013). Circulating levels of 25(OH)D
were low in patients with DFU (Asemi et al., 2013; Tiwari et al., 2013)
and the beneﬁcial effects of vitamin D supplementation on markers of
insulin resistance, biomarkers of inﬂammation and oxidative among
patients without DFU were reported. We have previously indicated
that supplementation with 50,000 IU vitamin D/week among patients
withmajor depressive disorder for 8 weeks had the beneﬁcial effects on
parameters of glucose homeostasis, and oxidative stress, but did not
affect lipid proﬁles (Sepehrmanesh et al., 2016). However, improve-
ment in vitamin D status following administration with 280 μg/day for
2 weeks and 140 μg/day for 10 weeks did not improve insulin
resistance among patients with diabetes (Kampmann et al., 2014).
The favorable effects of vitamin D supplementations on wound
healing, insulin resistance, biomarkers of inﬂammation and oxidative
stress may be mediated by its impact on stimulating the phagocytosis
and killing the bacteria by macrophages (van Etten, Decallonne,
Bouillon, & Mathieu, 2004), suppressing interferon-g-mediated
macrophage activation (Helming et al., 2005), activating insulin
receptor expression, and the downregulation of cytokine generation
(Pittas, Lau, Hu, & Dawson-Hughes, 2007). As there is evidence that
vitamin D intake may accelerate wound healing and has
anti-inﬂammatory and antioxidant effects, we hypothesized that
vitamin D supplementationmight help patients with DFU to heal their
wound faster, and have better metabolic proﬁles, and biomarkers of
inﬂammation and oxidative stress. The objective of this study was to
evaluate the effects of vitamin D supplementation on wound healing
and metabolic status in patients with DFU.
2. Methods
2.1. Trial design
The current study was a prospective randomized double-blind
placebo-controlled clinical trial.
2.2. Participants
In the current study, 60 patients with grade 3 DFU aged
40–85 years who referred to the Shahid Beheshti Clinic in Kashan,
Iran, between November 2015 and January 2016 were recruited. The
Wagner–Meggitt’s original system has six grades of lesions. This
system assesses ulcer depth and the presence of osteomyelitis or
gangrene by using the following grades: grade 0 (pre-or postulcera-
tive lesion), grade 1 (partial/full thickness ulcer), grade 2 (probing to
tendon or capsule), grade 3 (deep ulcer with abscess or osteomye-
litis), grade 4 (partial foot gangrene), and grade 5 (whole foot
gangrene) (Jain, 2012). In the current study, all patients had the same
grade 3. Pregnant and breastfeeding patients, participants who
consumed vitamin D supplements during the past 3 months,
anticipated changes in medications throughout the study and patients
with history of diseases which inﬂuence the development of DFU
including chronic trauma were excluded.
2.3. Ethics statements
This trialwas conducted in accordancewith theDeclarationofHelsinki
and informed consent was received from all patients. The research was
approved by the ethics committee of Kashan University of Medical
Sciences (KUMS) andwas recorded in the Iranianwebsite for registration
of clinical trials (http://www.irct.ir: IRCT201510315623N54).2.4. Study design
At the onset of the study, all participants were stratiﬁed for gender
(males: 22 and 8 females in each group), type and dosage of
medications, duration of diabetes mellitus (DM), pre-intervention
BMI (b25 and ≥25 kg/m2) and age (b55 and ≥55 years). Participants
were then randomly divided into two groups to receive either vitamin
D supplements (n = 30) or placebo (n = 30) for 12 weeks.
In addition, all participants underwent a similar treatment
protocol for the Diabetic Foot, based on the Infectious Diseases
Society of America (IDSA) (Berbari et al., 2015). Participants were
requested not to change their ordinary physical activity and not to
take any nutritional supplements during the 12-week trial. All
patients completed 3-day food records and three physical activity
records at the study baseline, weeks 3, 6 and 9 of the intervention and
end-of-the trial. Daily macro- and micro-nutrient intakes were
analyzed by nutritionist IV software (First Databank, San Bruno, CA).
In the current study, physical activity was described as metabolic
equivalents (METs) in hours per day. To determine the METs for each
patient, we multiplied the times (in hour per day) reported for each
physical activity by its related METs coefﬁcient by standard tables
(Ainsworth et al., 2000).
2.5. Intervention
In the intervention group, patients received 50,000 IU vitamin D
supplements every 2 weeks for 12 weeks. Vitamin D supplements
and placebos capsules were similar in shape and size and manufac-
tured by Zahravi (Tabriz, Iran).
2.6. Treatment adherence
Every four weeks, participants were given enough supplements to
last until 3 days after their next scheduled visit andwere instructed to
return all the unused supplements at each visit. Patients were
scheduled for the follow-up visits every 2 weeks at weeks 2, 4, 6, 8,
10 and 12 of the intervention for an intermediate evaluation and an
ulcer debridement as well as to complete 3-day food records and
three physical activity records at weeks 0, 3, 6, 9 and 12 of the
intervention. To determine the compliance the remaining supple-
ments were counted and subtracted from the amount of supplements
provided to the participants. To increase compliance, all participants
received short messages on their cell phones every day to remind
them about taking the capsules.
2.7. Assessment of anthropometric measures
Weight and height of participants were determined in an
overnight fasting status using a standard scale (Seca, Hamburg,
Germany) at the onset of the study and after 12-weeks’ intervention.
BMI was calculated as weight in kg divided by height in meters
squared.
2.8. Assessment of outcomes
In our study, wound healing and markers of insulin resistance
were considered as the primary outcome and lipid proﬁles, and
biomarkers of inﬂammation and oxidative stress were considered as
the secondary outcomes.
2.9. Clinical assessment
Ulcer size was measured by multiplying the largest by the second
largest perpendicular diameter of the skin lesion. Cumulative ulcer
size (sum of the two largest perpendicular diameters and ulcer depth)
was also computed for each patient. Depth of the ulcer was deﬁned as
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erythema, discharge, regional lymph node enlargement, pain, or
fever was present (Berbari et al., 2015). Patients were considered
positive for infection if at least two of the above listed features were
present. According to their location, ulcers were deﬁned as plantar or
nonplantar. Each foot was assessed and graded according to the
Wagner classiﬁcation (Berbari et al., 2015).
2.10. Biochemical assessment
Ten milliliters of fasting blood samples was collected at the
beginning and the end of the study at Kashan reference laboratory in a
fasting status and centrifuged to separate serum. Then, the samples
were stored at −80 °C before analysis. Serum 25-hydroxyvitamin D
concentrations were quantiﬁed by a commercial ELISA kit (IDS,
Boldon, UK) with inter- and intra-assay coefﬁcient variances (CVs) of
4.3% to 6.5%, respectively. Serum insulin concentrations were assessed
using available ELISA kit (DiaMetra, Milano, Italy). The homeostasis
model of assessment-insulin resistance (HOMA-IR), β-cell function
(HOMA-B) and the quantitative insulin sensitivity check index
(QUICKI) were determined according to the suggested formulas
(Pisprasert, Ingram, Lopez-Davila, Munoz, & Garvey, 2013). Hemo-
globin A1c (HbA1C) levels in the whole blood were quantiﬁed by
Glycomat kit (BiocodeHycel, Massy, France) using the method of
exchange chromatography. Enzymatic kits (Pars Azmun, Tehran, Iran)
were used to quantify FPG, serum triglycerides, VLDL-, total-, LDL- and
HDL-cholesterol concentrations. All inter- and intra-assay CVs for FPG
and lipid concentrations were less than 5%. Erythrocyte sedimentation
rate (ESR by Westergren method) was obtained at baseline and
12 weeks after starting treatment. Serum high sensitivity C-reactive
protein (hs-CRP) concentrations were evaluated by commercial ELISA
kit (LDN, Nordhorn, Germany). The plasma nitric oxide (NO)
concentrations were assessed using Griess method (Tatsch et al.,
2011). Plasma total antioxidant capacity (TAC) concentrations were
determined by the method of ferric reducing antioxidant power
developed byBenzie and Strain (1996), total glutathione (GSH) was
determined using the method of Beutler and Gelbart (1985) and
malondialdehyde (MDA) concentrations were determined by the
thiobarbituric acid reactive substances spectrophotometric test
(Janero, 1990). All inter- and intra-assay CVs for NO, TAC, GSH and
MDA concentrations were less than 5%.
2.11. Sample size
Using a formula suggested for clinical trials, having 25 patients in
each group was adequate while considering a type one error (α) of
0.05 and type two error (β) of 0.20 (power = 80%), 1.28 as SD and
1.00 as the mean distinction (d) of HOMA-IR as the key variable
(Asemi et al., 2013). Assuming 5 dropouts in each group, the ﬁnal
sample size was determined to be 30 patients in each group.
2.12. Randomization
Randomization assignment was performed using computer-
generated random numbers. Randomization and allocation were
concealed from the researchers and participants until the ﬁnal analyses
were completed. The randomized allocation sequence, enrolling
participants and allocating them to interventions were conducted by a
trained staff at the clinic.
2.13. Statistical methods
To evaluatewhether the study variables were normally distributed
or not, we used the Kolmogrov–Smirnov test. Analyses were
conducted based on an intention-to-treat (ITT) principle. Missing
values were treated based on Last-Observation-Carried-Forwardmethod (LOCF) (Lachin, 2016). LOCF ignores whether the partici-
pant's condition was improving or deteriorating at the time of
dropout but instead freezes outcomes at the value observed before
dropout (i.e., last observation) (Lachin, 2016). To detect differences in
anthropometric measures as well as in macro- and micro-nutrient
intakes between the two groups, we applied Student’s t test to
independent samples. To determine the effects of vitamin D
administration on ulcer size, markers of insulin resistance, lipid
proﬁles, biomarkers of inﬂammation and oxidative stress, we used
one-way repeated measures analysis of variance. In this analysis, the
treatment (vitamin D vs. placebo group) was regarded as a
between-subject factor and time with two time-points (the onset of
the study and after 12-intervention) was considered as within-subject
factor. To identify within-group differences (baseline and end-of-trial),
we used paired-samples t-tests. Differences in proportions were
evaluated by Chi square test or Fisher’s exact tests. In addition, to identify
within-group differences (baseline and end-of-trial) of nominal vari-
ables, we used the non-parametric McNemar test. Adjustment for
changes in baseline values of biochemical parameters, age and BMI at the
baseline was performed by analysis of covariance (ANCOVA) using
general linear models. The P-value of b0.05 was considered statistically
signiﬁcant. All statistical analyses used the Statistical Package for Social
Science version 18 (SPSS Inc., Chicago, IL, USA).3. Results
Among participants in the placebo group, 2 patients [withdrawn
for personal reasons (n = 2)] were excluded (Fig. 1). At the end, 58
patients with DUF [vitamin D (n = 30) and placebo (n = 28)]
completed the trial. However, as the analysis was based on the ITT
principle, all 60 patients (30 in each group) were included in the ﬁnal
analyses.
Gender distribution, mean age, weight and BMI at the baseline and
end-of-trial, METs at the baseline and end-of-trial, and insulin and
metformin therapy were not statistically different between the two
groups (Table 1). Mean height of study participants in the vitamin D
group was taller than in the placebo group (173.6 ± 7.3 vs.169.9 ±
6.2 cm, P = 0.03).
Based on the 3-day dietary records obtained at the baseline,
end-of-trial and throughout the trial, we found no signiﬁcant
difference in mean dietary macro- and micro-nutrient intakes
between the two groups (Table 2).
After 12 weeks of intervention, compared with the placebo,
vitamin D supplementation resulted in a signiﬁcant reduction in
ulcer length (−2.1 ± 1.1 vs. −1.1 ± 1.1 cm, P = 0.001), width
(−2.0 ± 1.2 vs.−1.1 ± 1.0 cm, P = 0.02) and depth (−1.0 ± 0.5
vs. −0.5 ± 0.5 cm, P b 0.001) (Fig. 2). In addition, vitamin D
supplementation led to a signiﬁcant decrease in HOMA-IR (−1.5 ±
4.1 vs. +1.7 ± 5.1, P = 0.01) compared with the placebo.
Compared with the placebo, vitamin D supplementation led to a
signiﬁcant rise in serum 25-hydroxyvitamin D levels (+12.9 ± 10.0
vs. −1.8 ± 15.7 ng/mL, P b 0.001) (Table 3). In addition, in supple-
mented patients changes in serum insulin concentration (−3.4 ± 9.2
vs. +2.8 ± 9.3 μIU/mL, P = 0.01), HOMA-B (−7.7 ± 23.7
vs. +4.2 ± 18.8, P = 0.03), QUICKI (+0.006 ± 0.02 vs. −0.006 ±
0.02, P = 0.03) and HbA1c (−0.6 ± 0.6 vs.−0.1 ± 0.5%, P =0.004)
were signiﬁcantly different from those of patients in the placebo
group. Additionally, following supplementation with vitamin D,
signiﬁcant reductions in serum total- (−15.8 ± 18.9 vs. +5.3 ±
31.8 mg/dL, P = 0.003), LDL- (−17.2 ± 19.8 vs.+2.2 ± 28.6 mg/dL,
P = 0.003), total-/HDL-cholesterol ratio (−1.1 ± 0.8 vs.−0.2 ± 1.1,
P = 0.001), hs-CRP (−0.4 ± 2.5 vs. +1.9 ± 4.2 μg/mL, P = 0.01),
ESR (−34.7 ± 32.4 vs. −18.0 ± 26.6 mm/h, P = 0.03) and plasma
MDA concentrations (−0.7 ± 0.9 vs.−0.2 ± 0.5 μmol/L, P = 0.008)
were seen compared with the placebo. There were no signiﬁcant
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Fig. 1. Summary of patient ﬂow diagram.
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oxidative stress between the two groups.
When we adjusted the analysis for baseline values of biochemical
parameters, age and baseline BMI, no signiﬁcant change in our
ﬁndings was observed except for FPG (P = 0.01) and HOMA-B (P =
0.09) (Table 4). Further adjustment for insulin andmetformin therapy
did not inﬂuence our ﬁndings.4. Discussion
In this trial, which to the best of our knowledge is the ﬁrst of its
kind, we evaluated effects of vitamin D supplementation on wound
healing, glycemia status, lipid concentrations, and biomarkers of
inﬂammation and oxidative stress among patients with DFU. WeTable 1
General characteristics of study participants.
Placebo group
(n = 30)
Vitamin D group
(n = 30)
P Valuea
Gender (%)
Male 22 (73.3) 22 (73.3) 1.00b
Female 8 (26.7) 8 (26.7)
Age (y) 58.6 ± 8.6 59.6 ± 8.2 0.64
Height (cm) 169.9 ± 6.2 173.6 ± 7.3 0.03
Weight at study baseline (kg) 75.5 ± 11.8 78.5 ± 14.3 0.37
Weight at end-of-trial (kg) 75.6 ± 11.8 78.6 ± 14.2 0.39
Weight change (kg) 0.1 ± 1.8 0.1 ± 1.1 0.76
BMI at study baseline (kg/m2) 26.2 ± 3.8 26.0 ± 4.4 0.90
BMI at end-of-trial (kg/m2) 26.2 ± 3.9 26.0 ± 4.3 0.86
BMI change (kg/m2) 0.05 ± 0.6 0.008 ± 0.4 0.70
MET-h/day at study baseline 26.0 ± 2.5 26.8 ± 2.7 0.27
MET-h/day at end-of-trial 25.8 ± 2.6 26.8 ± 2.8 0.19
MET-h/day change −0.1 ± 0.8 −0.01 ± 0.9 0.44
Insulin therapy (%) 30 (100.0) 30 (100.0) 1.00b
Metformin therapy (%) 27 (90.0) 26 (86.7) 0.68b
Data are means ± SDs.
METs, metabolic equivalents.
a Obtained from independent t test.
b Obtained from Pearson Chi-square test.demonstrated that vitamin D supplementation for 12 weeks among
patients with DFU had beneﬁcial effects on glucose homeostasis,
total-, LDL-, total-/HDL-cholesterol, ESR, hs-CRP andMDA levels, but it
did not had any effect on FPG, other lipid proﬁles, and biomarkers of
inﬂammation and oxidative stress. In addition, vitamin D may have
played an indirect role in wound healing due to its effect on improved
glycemic control.
We found that vitamin D supplementation among patients with
DFU for 12 weeks resulted in a signiﬁcant improve in parameters of
wound healing compared with the placebo. Few observational studies
have reported that the prevalence and severity of vitamin D deﬁciency
were high in patients with DFU (Tiwari, Pratyush, Gupta, & Singh,
2014; Tiwari et al., 2013). Hyperglycemia in diabetic patients disrupts
the normal process of cytokine production (Naguib, Al-Mashat, Desta,
& Graves, 2004), which in turn leads to the development of chronic
wound (Agren et al., 2000). In addition, several physiological factors
such as decreased growth factor production (Galkowska, Wojewodzka,
& Olszewski, 2006), macrophage function (Maruyama et al., 2007) andTable 2
Dietary intakes of study participants throughout the study.
Placebo group
(n = 30)
Vitamin D group
(n = 30)
P Valuea
Energy (kcal/d) 2165 ± 210 2238 ± 217 0.19
Carbohydrates (g/d) 299.6 ± 43.0 310.3 ± 50.0 0.37
Protein (g/d) 80.3 ± 19.1 80.9 ± 11.2 0.89
Fat (g/d) 75.7 ± 13.8 78.3 ± 14.0 0.46
SFAs (g/d) 23.5 ± 4.9 24.6 ± 4.6 0.35
PUFAs (g/d) 23.3 ± 5.5 24.3 ± 6.3 0.54
MUFAs (g/d) 20.7 ± 6.0 21.3 ± 5.6 0.70
Cholesterol (mg/d) 188.0 ± 106.3 198.0 ± 106.3 0.71
TDF (g/d) 19.7 ± 4.3 18.3 ± 4.3 0.22
Vitamin D (μg/d) 2.9 ± 0.8 3.0 ± 0.9 0.69
Calcium (mg/d) 1073.4 ± 146.9 1116.6 ± 185.7 0.32
Data are means ± SDs.
MUFAs, monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids; SFAs
saturated fatty acids; TDF, total dietary ﬁber.
a Obtained from independent t test.,
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Fig. 2. Scatter-gram of mean changes in ulcer size and HOMA-IR after 12 weeks of intervention. HOMA-IR, homeostasis model of assessment-estimated insulin resistance.
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wound-healing abnormalities in individuals with diabetes. Previous
studies have suggested that vitamin D deﬁciency is associated with
increased susceptibility towards infection (Tiwari et al., 2013).
Furthermore, it has been shown that active vitamin D3 stimulates the
phagocytosis and killing of the intestine bacteria by macrophages (van
Etten et al., 2004) and is a potent suppressor of the interferon-
g-mediated macrophage activation (Lemire., 1992). Vitamin D also
suppresses T cell proliferation and decreases the production of T helper
type 1 cytokines, while promoting the production of T helper type 2
cytokines (van Etten &Mathieu, 2005), whichmay improve parameters
of wound healing.
Findings of the current study demonstrated that vitamin D
administration compared with the placebo in patients with DFU for
12 weeks led to signiﬁcant reductions in serum insulin, HOMA-IR,
HOMA-B, HbA1c, serum total- and LDL- and total-/HDL-cholesterol,
and a signiﬁcant increase in QUICKI, but did not affect FPG and other
lipid proﬁles. Observational studies have indicated that low
25-hydroxyvitamin D [25(OH)D] levels were associated with im-
paired in glucose homeostasis parameters (Ferreira Tda, Rocha, Klein,
& Sanjuliani, 2015). It is difﬁcult to determine a solid rationale for such
associations, unless there was an effect of vitamin D administration on
markers of insulin resistance in placebo-controlled randomized trials.
Unfortunately, the intervention studies gave controversial results
with some showing a positive and some a negative effect. We have
previously shown that supplementation with 50,000 IU vitamin D/
every two weeks for 12 weeks among women at risk of pre-eclampsiaimprovedmarkers of insulin resistance (Karamali, Beihaghi,Mohammadi,
& Asemi, 2015). However, supplementationwith 1000 IU/day vitaminD
among healthy overweight or obese women for 12 weeks did not
inﬂuence insulin resistance (Salehpour et al., 2013). About the effects of
vitamin D on lipid proﬁles, several experimental and clinical studies
previously demonstrated that vitamin D supplements have decreasing
effects on serum lipid proﬁles. Supplementation with 4000 IU/day
vitamin D in postmenopausal women with type 2 diabetes mellitus
(T2DM) for 6 months resulted in a signiﬁcant decrease in serum
triglyceride levels without affecting levels of other lipid proﬁles
(Munoz-Aguirre et al., 2015). No signiﬁcant change in circulating levels
of triglycerides, LDL- andHDL-cholesterolwasobserved inpatientswith
T2DM following supplementation with 16,000 IU of vitamin D orally
once a week for 8 weeks (Ramiro-Lozano & Calvo-Romero, 2015).
Favorable effects of vitamin D intake on markers of insulin resistance
might be explained by its effect on calcium and phosphorusmetabolism
and through up-regulation of the insulin receptor genes (Maestro,
Molero, Bajo, Davila,&Calle, 2002) and increased transcription of insulin
receptor genes (Maestro et al., 2002). Moreover, fewmechanisms could
explain the effect of vitamin D on decreasing concentrations of lipid and
lipoproteins. VitaminD intakemight increase calciumabsorption,which
in turn would result in increasing fat absorption (Reid, 2004). In
addition, vitamin D through improved insulin sensitivitymightmediate
its potential beneﬁt on lipid proﬁles (Rajpathak et al., 2010).
This study showed that compared with the placebo, taking vitamin
D supplements for 12 weeks among patients with DFU decreased
serum hs-CRP, ESR and plasma MDA concentrations, but did not
Table 3
Wound healing, metabolic proﬁles, and biomarkers of inﬂammation and oxidative stress at the baseline and after 12 weeks of the intervention in patients with diabetic foot ulcer.
Placebo group (n = 30) Vitamin D group (n = 30) P Valueb
Baseline End-of-trial Change P Valuea Baseline End-of-trial Change P Valuea
Vitamin D (ng/mL) 20.2 ± 15.6 18.4 ± 8.5 −1.8 ± 15.7 0.52 15.2 ± 9.9 28.1 ± 12.5 12.9 ± 10.0 b0.001 b0.001
Ulcer symptoms
Erythema (%) 30 (100) 6 (20) – b0.001c 30 (100) 0 (0) – b0.001c 0.01d
Discharge (%) 30 (100) 5 (16.7) – b0.001c 30 (100) 1 (3.3) – b0.001c 0.08d
Necrosis (%) 9 (30) 3 (10) – 0.002c 6 (20) 0 (0) – 0.03c 0.18d
FPG (mg/dL) 187.8 ± 70.7 174.4 ± 68.5 −13.4 ± 48.3 0.13 171.8 ± 62.2 140.5 ± 31.9 −31.3 ± 46.4 0.001 0.14
Insulin (μIU/mL) 15.0 ± 6.3 17.8 ± 8.5 2.8 ± 9.3 0.10 17.1 ± 9.4 13.7 ± 6.4 −3.4 ± 9.2 0.05 0.01
HOMA-B 29.4 ± 20.1 33.6 ± 19.7 4.2 ± 18.8 0.23 36.9 ± 29.0 29.2 ± 20.1 −7.7 ± 23.7 0.08 0.03
QUICKI 0.29 ± 0.01 0.29 ± 0.02 −0.006 ± 0.02 0.18 0.30 ± 0.03 0.30 ± 0.002 0.006 ± 0.02 0.15 0.03
HbA1c (%) 7.8 ± 0.7 7.7 ± 0.6 −0.1 ± 0.5 0.20 8.3 ± 1.0 7.7 ± 0.5 −0.6 ± 0.6 b0.001 0.004
Triglycerides (mg/dL) 154.2 ± 93.1 151.7 ± 104.0 −2.5 ± 36.7 0.71 163.4 ± 66.5 147.5 ± 50.7 −15.9 ± 25.1 0.002 0.10
VLDL-cholesterol (mg/dL) 30.8 ± 18.6 30.3 ± 20.8 −0.5 ± 7.3 0.71 32.7 ± 13.3 29.5 ± 10.1 −3.2 ± 5.0 0.002 0.10
Total cholesterol (mg/dL) 159.4 ± 45.0 164.7 ± 49.2 5.3 ± 31.8 0.37 177.5 ± 35.3 161.7 ± 31.2 −15.8 ± 18.9 b0.001 0.003
LDL-cholesterol (mg/dL) 96.5 ± 38.1 98.7 ± 41.3 2.2 ± 28.6 0.68 112.1 ± 31.5 94.9 ± 30.3 −17.2 ± 19.8 b0.001 0.003
HDL-cholesterol (mg/dL) 32.0 ± 4.5 35.6 ± 6.2 3.6 ± 6.5 0.005 32.7 ± 3.6 37.4 ± 3.9 4.6 ± 4.1 b0.001 0.46
Total-/HDL-cholesterol ratio 5.0 ± 1.3 4.8 ± 1.8 −0.2 ± 1.1 0.27 5.5 ± 1.2 4.4 ± 1.0 −1.1 ± 0.8 b0.001 0.001
hs-CRP (μg/mL) 15.4 ± 5.6 17.3 ± 5.2 1.9 ± 4.2 0.01 13.2 ± 3.9 12.8 ± 4.2 −0.4 ± 2.5 0.34 0.01
ESR (mm/h) 64.5 ± 36.8 46.5 ± 30.7 −18.0 ± 26.6 0.001 67.1 ± 35.8 32.4 ± 19.7 −34.7 ± 32.4 b0.001 0.03
NO (μmol/L) 43.1 ± 4.6 44.8 ± 5.7 1.7 ± 6.8 0.17 40.6 ± 8.9 45.0 ± 5.3 4.4 ± 9.6 0.01 0.22
TAC (mmol/L) 1295.6 ± 134.2 1200.8 ± 180.5 −94.8 ± 172.6 0.005 1314.1 ± 98.8 1219.2 ± 180.5 −94.9 ± 192.6 0.01 0.99
GSH (μmol/L) 540.0 ± 98.3 500.4 ± 82.7 −39.5 ± 131.1 0.10 551.0 ± 106.1 514.5 ± 90.9 −36.5 ± 136.1 0.15 0.93
MDA (μmol/L) 3.7 ± 0.7 3.5 ± 0.6 −0.2 ± 0.5 0.007 3.9 ± 0.8 3.2 ± 0.6 −0.7 ± 0.9 b0.001 0.008
All values are means ± SDs.
ESR, erythrocyte sedimentation rate; FPG, fasting plasma glucose; GSH, total glutathione; HOMA-B, homeostasis model of assessment-estimated B cell function; HbA1C, hemoglobin
A1c; hs-CRP, high-sensitivity C-reactive protein; MDA, malondialdehyde; NO, nitric oxide; QUICKI, quantitative insulin sensitivity check index; TAC, total antioxidant capacity.
a P values represent paired-samples t-test.
b P values represent the time × group interaction (computed by analysis of the one-way repeated measures ANOVA).
c Obtained from McNemar test.
d Obtained from Chi-square test.
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Previous observational and intervention studies have reported that
supplemental vitamin Dmay have anti-inﬂammatory and antioxidantTable 4
Adjusted changes in metabolic proﬁle of the patients with diabetic foot ulcer.
Placebo group
(n = 30)
Vitamin D group
(n = 30)
P Valuea
Vitamin D (ng/mL) −0.005 ± 1.8 11.1 ± 1.8 b0.001
Ulcer length (cm) −1.1 ± 0.2 −2.1 ± 0.2 0.001
Ulcer width (cm) −1.1 ± 0.2 −1.9 ± 0.2 0.01
Ulcer depth (cm) −0.5 ± 0.1 −1.0 ± 0.1 b0.001
FPG (mg/dL) −9.3 ± 6.9 −35.5 ± 6.9 0.01
Insulin (μIU/mL) 2.0 ± 1.4 −2.6 ± 1.4 0.02
HOMA-IR 1.6 ± 0.8 −1.4 ± 0.8 0.009
HOMA-B 2.0 ± 3.1 −5.5 ± 3.1 0.09
QUICKI −0.007 ± 0.003 0.007 ± 0.003 0.008
HbA1c (%) −0.2 ± 0.1 −0.5 ± 0.1 0.04
Triglycerides (mg/dL) −2.4 ± 5.7 −16.0 ± 5.7 0.09
VLDL-cholesterol (mg/dL) −0.5 ± 1.1 −3.2 ± 1.1 0.09
Total cholesterol (mg/dL) 3.4 ± 4.7 −13.9 ± 4.7 0.01
LDL-cholesterol (mg/dL) 0.3 ± 4.4 −15.3 ± 4.4 0.01
HDL-cholesterol (mg/dL) 3.4 ± 0.9 4.9 ± 0.9 0.25
Total-/HDL-cholesterol ratio −0.2 ± 0.2 −1.1 ± 0.2 0.003
hs-CRP (μg/mL) 2.2 ± 0.6 −0.7 ± 0.6 0.001
ESR (mm/h) −19.1 ± 3.7 −33.6 ± 3.7 0.008
NO (μmol/L) 2.8 ± 1.0 3.3 ± 1.0 0.75
TAC (mmol/L) −99.1 ± 32.1 −90.6 ± 32.1 0.85
GSH (μmol/L) −44.7 ± 16.3 −31.3 ± 16.3 0.56
MDA (μmol/L) −0.3 ± 0.1 −0.7 ± 0.1 0.01
All values are means ± SEs. Values are adjusted for baseline values, age and BMI at
baseline.
ESR, erythrocyte sedimentation rate; FPG, fasting plasma glucose; GSH, total
glutathione; HOMA-IR, homeostasis model of assessment-estimated insulin
resistance; HOMA-B, homeostasis model of assessment-estimated B cell function;
HbA1C, hemoglobin A1c; hs-CRP, high-sensitivity C-reactive protein; MDA,
malondialdehyde; NO, nitric oxide; QUICKI, quantitative insulin sensitivity check
index; TAC, total antioxidant capacity.
a Obtained from ANCOVA.effect; nonetheless, results across all completed randomized trials
have been inconsistent. Supporting with our study, supplementation
of 60,000 IU/month vitamin D in rheumatoid arthritis patients with
persisting disease activity and vitamin D deﬁciency for 3 months led
to signiﬁcant improvement in CRP levels (Chandrashekara & Patted,
2015). In addition, a 3-month treatment with 2000 IU/day vitamin D
in Crohn's disease signiﬁcantly decreased CRP levels (Raftery et al.,
2015). However, our previous study among patients with major
depressive disorder for 8 weeks have indicated that taking 50,000 IU/
week vitamin D supplements did not inﬂuence hs-CRP levels, but
increased TAC and GSH concentrations (Sepehrmanesh et al., 2016).
Less production of parathyroid hormone following supplementation
of vitamin D (Struglia et al., 2015) might result to a reduction in
production of inﬂammatory factors including CRP. The accurate
mechanisms by which vitamin D intake might inﬂuence biomarkers
of oxidative stress are unknown. Improvement in the cellular GSH
levels, decreasing the production of reactive oxygen species and
pro-inﬂammatory markers by vitamin D supplements may explain
the favorable effects on oxidative stress (42).
The current study had few limitations. The sample size was small.
Future studies with bigger sample size are needed to conﬁrm the
validity of our ﬁndings. Baseline HbA1c levels were different between
the two groups. There was a signiﬁcant improvement in HbA1c levels
in the vitamin D group, which further complicated the situation such
that it is would be difﬁcult to extricate the effect of lowering glucose
from that of vitamin D supplementation on wound healing, mainly as
the baseline HbA1c levels were higher in the vitamin D group. It must
be taken into account that there was a difference in serum vitamin D
levels between the vitamin D and the placebo groups at study
baseline. The difference in serum vitamin D levels between the two
groups occurred at random. In addition, when we adjusted the
analyses for baseline values of biochemical variables, no signiﬁcant
changes in our ﬁndings were observed. Although we agree that if they
had similar levels to begin with, it would be even more interesting to
know if supplementation of vitamin D made a difference to wound
772 R. Razzaghi et al. / Journal of Diabetes and Its Complications 31 (2017) 766–772healing. Future studies are needed to conﬁrm our ﬁndings. Further-
more, in the current study, insulin and metformin therapy were not
statistically signiﬁcant different between the two groups. This data
were taken from a 'yes/no' question. Since all patients were on insulin,
it is very likely that the doses were changed during the study, which
may have inﬂuenced results. Therefore, our ﬁndings should be
interpreted with caution. Overall, vitamin D supplementation for
12 weeks among patients with DFU had beneﬁcial effects on glucose
homeostasis, total-, LDL-, total-/HDL-cholesterol, ESR, hs-CRP and
MDA levels. In addition, vitamin Dmay have played an indirect role in
wound healing due to its effect on improved glycemic control.Acknowledgments
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